Harnessing the healing power of oxygen
Striving to protect people from C. difficile colitis superinfections and those suffering from inflammatory bowel diseases.
Addressing an urgent public health threat
We are focused on the prevention of bacterial infections, with a primary emphasis on tackling C. difficile, a leading cause of healthcare-associated infections.
Our innovative platform is designed to reduce the healthcare and economic burden associated with bacterial infections, particularly in vulnerable patient populations. With a strategic focus on impactful clinical development, LPOXY aims to deliver significant value to patients and stakeholders alike.
The LPOXY team is driven to protect people from this deadly antibiotic-induced superinfection.
- The Centers for Disease Control and Prevention considers C. difficile colitis an URGENT public health threat.
- C. difficile colitis afflicts nearly a half million Americans each year.
- 30,000 will die.
- There are no therapies or vaccines to prevent this antibiotic-induced superinfection.
LPOXY Therapeutics is developing a pill that taken with antibiotics gently increases the colon’s oxygen tension and prevents antibiotic-induced C. difficile colitis via three mechanisms.
Watch a video about antibiotics and C. difficile colitis here.
SIDIPREV™ orally-administered, metered-dose intestinal oxygen delivery is being developed for multiple indications
-
Antibiotic-induced C. difficile colitis superinfection prevention
Oxygen’s clinical effectiveness established in humans
-
Inflammatory Bowel Diseases: Crohn's & Ulcerative Colitis
Oxygen’s clinical effectiveness established in humans
-
Multiple Sclerosis
Via oxygen’s effectiveness vs epsilon-toxin-producing C. perfringens
